Clinical trialsCompany release

IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach

🇺🇸 IRulya Therapeutics Inc. (IRLA) · Fri 13 Nov 2026

The company formerly known as Quince Therapeutics says its inhaled rapamycin programme will read out first in post-lung-transplant BOS in Q1 2027, with cash expected to last through 2028.

IRulya Therapeutics, previously Quince Therapeutics, published its third-quarter 2026 results and a corporate update on 13 November 2026. The company now centres its pipeline on LAM-001, an inhaled formulation of rapamycin.

The next clinical milestone is Phase 2 data in bronchiolitis obliterans syndrome (BOS) after lung transplant, which the company expects in the first quarter of 2027. A Phase 2 readout in pulmonary hypertension associated with interstitial lung disease (PH-ILD) is scheduled for the first quarter of 2028.

IRulya also plans a study of LAM-001 in sarcoidosis-associated pulmonary hypertension. No further details on that study were available in the information provided.

The company reported cash of $105.2 million, which it expects to fund operations through 2028. It changed its name and began trading on Nasdaq under the ticker IRLA in October 2026.

What it means for your team

  • Regulatory teams tracking inhaled therapies for transplant and pulmonary vascular disease should note the Q1 2027 BOS readout as the first LAM-001 data point.
  • The programme spans several rare or hard-to-treat respiratory indications, so future submissions will depend on the Phase 2 results; none have been reported yet.
  • Anyone maintaining company or product records should update Quince Therapeutics references to IRulya Therapeutics (Nasdaq: IRLA).

Company's press release (SEC filing): IRulya Therapeutics Inc. ↗

Article written by VigiEye from the official source (IRulya Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →